Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache.
We treated 64 emergency room patients with a primary vascular headache with dihydroergotamine (DHE), meperidine, or butorphanol. Post-treatment pain scores were lowest in the DHE group (p less than 0.01). Eight of 21 patients receiving DHE had greater than 90% reduction in pain compared with three of 19 patients receiving butorphanol and none of 22 receiving meperidine.
Belgrade
M J
MJ
Department of Neurology, Hennepin County Medical Center, Minneapolis, MN 55415.
Ling
L J
LJ
Schleevogt
M B
MB
Ettinger
M G
MG
Ruiz
E
E
D000328:Adult; D002077:Butorphanol / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D008297:Male; D008614:Meperidine / Q000627:therapeutic use*; D008787:Metoclopramide / Q000627:therapeutic use; D009019:Morphinans / Q000627:therapeutic use*; D014653:Vascular Headaches / Q000188:drug therapy*
D009019:Morphinans; D006919:Hydroxyzine; D004087:Dihydroergotamine; D008614:Meperidine; D008787:Metoclopramide; D002077:Butorphanol